BACE1 inhibitor drugs in clinical trials for Alzheimer's disease

Alzheimer's Research and Therapy

Volumn 6, Issue 9, 2014, Pages

  Vassar, Robert ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIHYDRO 2 IMINO 3 METHYL 6 [4 [5 (1 PROPYNYL) 3 PYRIDINYL] 2 THIENYL] 4 PYRIMIDINONE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AZD 3293; BETA SECRETASE 1 INHIBITOR; BETA SECRETASE INHIBITOR; E 2609; ENZYME ANTIBODY; LY 2811376; LY 2886721; PEPTIDOMIMETIC AGENT; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BINDING AFFINITY; BIOACCUMULATION; BLOOD BRAIN BARRIER; BRAIN DISEASE; CHRONIC DRUG ADMINISTRATION; DOSE RESPONSE; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; IMMUNOTHERAPY; LIVER DISEASE; MILD COGNITIVE IMPAIRMENT; NONHUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN CLEAVAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA DISEASE; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

EID: 84928122845     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-014-0089-7     Document Type: Review

References (108)

1. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
2. Tanzi RE: The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2012, 2.
3. Rutten BP, Steinbusch HW: Current concepts in Alzheimer's Disease: molecules, models and translational perspectives. Mol Neurodegener 2013, 8:33.
4. Vassar R, Kovacs DM, Yan R, Wong PC: The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 2009, 29:12787-12794.
5. Sisodia SS, St George-Hyslop PH: gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 2002, 3:281-290.
6. De Strooper B, Vassar R, Golde T: The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010, 6:99-107.
7. Walter J, van Echten-Deckert G: Cross-talk of membrane lipids and Alzheimer-related proteins. Mol Neurodegener 2013, 8:34.
8. Mullan M, Crawford F, Houlden H, Axelman K, Lilius L, Winblad B, Lannfelt L: A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1992, 1:345-347.
9. Di Fede G, Catania M, Morbin M, Rossi G, Suardi S, Mazzoleni G, Merlin M, Giovagnoli AR, Prioni S, Erbetta A, Falcone C, Gobbi M, Colombo L, Bastone A, Beeg M, Manzoni C, Francescucci B, Spagnoli A, Cantu L, Del Favero E, Levy E, Salmona M, Tagliavini F: A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009, 323:1473-1477.
10. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jonsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K: A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488:96-99.
11. Maloney JA, Bainbridge T, Gustafson A, Zhang S, Kyauk R, Steiner P, van der Brug M, Liu Y, Ernst JA, Watts RJ, Atwal JK: Molecular mechanisms of Alzheimer disease protection by the A673T Allele of amyloid precursor protein. J Biol Chem 2014, 289:30990-31000.
12. Benilova I, Gallardo R, Ungureanu AA, Castillo Cano V, Snellinx A, Ramakers M, Bartic C, Rousseau F, Schymkowitz J, De Strooper B: The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of Amyloid-beta (Abeta) aggregation. J Biol Chem 2014, 289:30977-30989.
13. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M: Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
14. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gurney ME: Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 1999, 402:533-537.
15. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L, John V: Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999, 402:537-540.
16. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS, Simmons DL, Walsh FS, Dingwall C, Christie G: Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 1999, 14:419-427.
17. Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J: Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci U S A 2000, 97:1456-1460.
18. Solans A, Estivill X, de La Luna S: A new aspartyl protease on 21q22.3, BACE2, is highly similar to Alzheimer's amyloid precursor protein betasecretase. Cytogenet Cell Genet 2000, 89:177-184.
19. Bennett BD, Babu-Khan S, Loeloff R, Louis JC, Curran E, Citron M, Vassar R: Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem 2000, 275:20647-20651.
20. Laird FM, Cai H, Savonenko AV, Farah MH, He K, Melnikova T, Wen H, Chiang HC, Xu G, Koliatsos VE, Borchelt DR, Price DL, Lee HK, Wong PC: BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 2005, 25:11693-11709.
21. Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H: BACE2, a b-secretase homolog, cleaves at the b site and within the amyloid-b region of the amyloid-b precursor protein. Proc Natl Acad Sci U S A 2000, 97:9712-9717.
22. Yan R, Munzner JB, Shuck ME, Bienkowski MJ: BACE2 functions as an alternative alpha-secretase in cells. J Biol Chem 2001, 276:34019-34027.
23. Fluhrer R, Capell A, Westmeyer G, Willem M, Hartung B, Condron MM, Teplow DB, Haass C, Walter J: A non-amyloidogenic function of BACE-2 in the secretory pathway. J Neurochem 2002, 81:1011-1020.
24. Basi G, Frigon N, Barbour R, Doan T, Gordon G, McConlogue L, Sinha S, Zeller M: Antagonistic effects of beta-site amyloid precursor proteincleaving enzymes 1 and 2 on beta-amyloid peptide production in cells. J Biol Chem 2003, 278:31512-31520.
25. Abdul-Hay SO, Sahara T, McBride M, Kang D, Leissring MA: Identification of BACE2 as an avid ss-amyloid-degrading protease. Mol Neurodegener 2012, 7:46.
26. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R: Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 2001, 4:231-232.
27. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu W, Motter R, Nichols NF, Power M, Robertson DW, Schenk D, Schoor M, Shopp GM, Shuck ME, Sinha S, Svensson KA, Tatsuno G, Tintrup H, Wijsman J, et al: BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 2001, 10:1317-1324.
28. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC: BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 2001, 4:233-234.
29. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, Roebroek AJ, Schwake M, D'Hooge R, Bach P, Kalinke U, Moechars D, Alzheimer C, Reiss K, Saftig P, De Strooper B: Phenotypic and biochemical analyses of BACE1- And BACE2-deficient mice. J Biol Chem 2005, 280:30797-30806.
30. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF: BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 2004, 41:27-33.
31. Luo Y, Bolon B, Damore MA, Fitzpatrick D, Liu H, Zhang J, Yan Q, Vassar R, Citron M: BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol Dis 2003, 14:81-88.
32. Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M, Berry R, Disterhoft JF, Vassar R: BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol Dis 2007, 26:134-145.
33. McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, Games D, Johnson-Wood K, Lee M, Zeller M, Liu W, Motter R, Sinha S: Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem 2007, 282:26326-26334.
34. Kandalepas PC, Sadleir KR, Eimer WA, Zhao J, Nicholson DA, Vassar R: The Alzheimer's beta-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. Acta Neuropathol 2013, 126:329-352.
35. Deng M, He W, Tan Y, Han H, Hu X, Xia K, Zhang Z, Yan R: Increased expression of reticulon 3 in neurons leads to reduced axonal transport of beta site amyloid precursor protein-cleaving enzyme 1. J Biol Chem 2013, 288:30236-30245.
36. Rajapaksha TW, Eimer WA, Bozza TC, Vassar R: The Alzheimer's beta-secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and normal glomerulus formation in the olfactory bulb. Mol Neurodegener 2011, 6:88.
37. Cao L, Rickenbacher GT, Rodriguez S, Moulia TW, Albers MW: The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease. Sci Rep 2012, 2:231.
38. Hitt B, Riordan S, Kukreja L, Eimer W, Rajapaksha T, Vassar R: Beta-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects. J Biol Chem 2012, 287:38408-38425.
39. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C: Control of peripheral nerve myelination by the beta-secretase BACE1. Science 2006, 314:664-666.
40. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R: Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 2006, 9:1520-1525.
41. Hu X, He W, Diaconu C, Tang X, Kidd GJ, Macklin WB, Trapp BD, Yan R: Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. FASEB J 2008, 22:2970-2980.
42. Kobayashi D, Zeller M, Cole T, Buttini M, McConlogue L, Sinha S, Freedman S, Morris RG, Chen KS: BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease. Neurobiol Aging 2008, 29:861-873.
43. Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF: Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci 2006, 23:251-260.
44. Cheret C, Willem M, Fricker FR, Wende H, Wulf-Goldenberg A, Tahirovic S, Nave KA, Saftig P, Haass C, Garratt AN, Bennett DL, Birchmeier C: Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles. EMBO J 2013, 32:2015-2028.
45. Harrison SM, Harper AJ, Hawkins J, Duddy G, Grau E, Pugh PL, Winter PH, Shilliam CS, Hughes ZA, Dawson LA, Gonzalez MI, Upton N, Pangalos MN, Dingwall C: BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. Mol Cell Neurosci 2003, 24:646-655.
46. Hu X, He W, Luo X, Tsubota KE, Yan R: BACE1 Regulates Hippocampal Astrogenesis via the Jagged1-Notch Pathway. Cell Rep 2013, 4:40-49.
47. Hu X, Zhou X, He W, Yang J, Xiong W, Wong P, Wilson CG, Yan R: BACE1 deficiency causes altered neuronal activity and neurodegeneration. J Neurosci 2010, 30:8819-8829.
48. Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC: Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci U S A 2008, 105:5585-5590.
49. Cai J, Qi X, Kociok N, Skosyrski S, Emilio A, Ruan Q, Han S, Liu L, Chen Z, Bowes Rickman C, Golde T, Grant MB, Saftig P, Serneels L, de Strooper B, Joussen AM, Boulton ME: beta-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol Med 2012, 4:980-991.
50. Hitt BD, Jaramillo TC, Chetkovich DM, Vassar R: BACE1-/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. Mol Neurodegener 2010, 5:31.
51. Meakin PJ, Harper AJ, Hamilton DL, Gallagher J, McNeilly AD, Burgess LA, Vaanholt LM, Bannon KA, Latcham J, Hussain I, Speakman JR, Howlett DR, Ashford ML: Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. Biochem J 2012, 441:285-296.
52. Hoffmeister A, Tuennemann J, Sommerer I, Mossner J, Rittger A, Schleinitz D, Kratzsch J, Rosendahl J, Kloting N, Stahl T, Rossner S, Paroni F, Maedler K, Kovacs P, Blüher M: Genetic and biochemical evidence for a functional role of BACE1 in the regulation of insulin mRNA expression. Obesity (Silver Spring) 2013, 21:E626-E633.
53. Kim DY, Carey BW, Wang H, Ingano LA, Binshtok AM, Wertz MH, Pettingell WH, He P, Lee VM, Woolf CJ, Kovacs DM: BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat Cell Biol 2007, 9:755-764.
54. Esterhazy D, Stutzer I, Wang H, Rechsteiner MP, Beauchamp J, Dobeli H, Hilpert H, Matile H, Prummer M, Schmidt A, Lieske N, Boehm B, Marselli L, Bosco D, Kerr-Conte J, Aebersold R, Spinas GA, Moch H, Migliorini C, Stoffel M: Bace2 is a beta cell-enriched protease that regulates pancreatic beta cell function and mass. Cell Metab 2011, 14:365-377.
55. Rochin L, Hurbain I, Serneels L, Fort C, Watt B, Leblanc P, Marks MS, De Strooper B, Raposo G, van Niel G: BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells. Proc Natl Acad Sci U S A 2013, 110:10658-10663.
56. Kuhn PH, Koroniak K, Hogl S, Colombo A, Zeitschel U, Willem M, Volbracht C, Schepers U, Imhof A, Hoffmeister A, Haass C, Rossner S, Brase S, Lichtenthaler SF: Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J 2012, 31:3157-3168.
57. Zhou L, Barao S, Laga M, Bockstael K, Borgers M, Gijsen H, Annaert W, Moechars D, Mercken M, Gevaer K, De Strooper B: The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo. J Biol Chem 2012, 287:25927-25940.
58. Fleck D, van Bebber F, Colombo A, Galante C, Schwenk BM, Rabe L, Hampel H, Novak B, Kremmer E, Tahirovic S, Edbauer D, Lichtenthaler SF, Schmid B, Willem M, Haass C: Dual cleavage of neuregulin 1 type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling. J Neurosci 2013, 33:7856-7869.
59. Luo X, Prior M, He W, Hu X, Tang X, Shen W, Yadav S, Kiryu-Seo S, Miller R, Trapp BD, Yan R: Cleavage of neuregulin-1 by BACE1 or ADAM10 protein produces differential effects on myelination. J Biol Chem 2011, 286:23967-23974.
60. Heyden A, Angenstein F, Sallaz M, Seidenbecher C, Montag D: Abnormal axonal guidance and brain anatomy in mouse mutants for the cell recognition molecules close homolog of L1 and NgCAM-related cell adhesion molecule. Neuroscience 2008, 155:221-233.
61. Montag-Sallaz M, Schachner M, Montag D: Misguided axonal projections, neural cell adhesion molecule 180 mRNA upregulation, and altered behavior in mice deficient for the close homolog of L1. Mol Cell Biol 2002, 22:7967-7981.
62. Kopan R, Ilagan MX: The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009, 137:216-233.
63. Hong L, Turner RT 3rd, Koelsch G, Shin D, Ghosh AK, Tang J: Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3. Biochemistry 2002, 41:10963-10967.
64. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, Tang J: Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 2000, 290:150-153.
65. Probst G, Xu YZ: Small-molecule BACE1 inhibitors: A patent literature review (2006-2011). Expert Opin Ther Pat 2012, 22:511-540.
66. Evin G, Lessene G, Wilkins S: BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: focus on bioactivity. Recent Pat CNS Drug Discov 2011, 6:91-106.
67. Marques F, Sousa JC, Sousa N, Palha JA: Blood-brain-barriers in aging and in Alzheimer's disease. Mol Neurodegener 2013, 8:38.
68. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, Cocke PJ, Greg Hall D, Friedrich S, Citron M, Audia JE: Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci 2011, 31:16507-16516.
69. Martenyi F, Dean RA, Lowe S, Nakano M, Monk S, Willis BA, Gonzales C, Mergott D, Leslie D, May P, James A, Gevorkyan H, Jhee S, Ereshefsky L, Citron M: BACE inhibitor LY2886721 safety and central and peripheral PK and PD in healthy subjects (HSs). Alzheimers Dement 2012, 8:P583-P584.
70. Willis B, Martenyi F, Dean R, Lowe S, Nakano M, Monk S, Gonzales C, Mergott D, Daugherty L, Citron M, May P: Central BACE1 inhibition by LY2886721 produces opposing effects on APP processing as reflected by cerebrospinal fluid sAPPalpha and sAPPbeta. Alzheimers Dement 2012, 8:P582.
71. May PC, Mergott DJ, Cocke PJ, Monk SA, Boggs LN, Sanchez-Felix MV, Audia JE, Calligaro DO, Citron M, Dean RA, Lowe SL, Daugherty LL, Gonzales CR, Nakano M, Willis BA, Martenyi F: Preclinical and Phase I clinical characterization of LY2886721, a BACE inhibitor in Phase II development Alzheimer's disease. The 11th International Conference On Alzheimer's & Parkinson's Diseases, Florence, Italy, March 6-10, 2013.
72. Forman M, Palcza J, Tseng J, Leempoels J, Ramael S, Han D, Jhee S, Ereshefsky L, Tanen M, Laterza O, Dockendorf M, Krishna G, Ma L, Wagner J, Troyer M: The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Aβ peptides in health subjects following single- And multiple-dose administration. Alzheimers Dement 2012, 8:P704.
73. Forman M, Kleijn H, Dockendorf M, Palcza J, Tseng J, Canales C, Egan M, Kennedy M, Laterza O, Ma L, Scott J, TanenM, Apter J, Backonja M, Ereshefsky L, Gevorkyan H, Jhee S, Rynders R, Zari A, Bryan E, Wagner J, Troyer M, Stone J: The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease. Alzheimers Dement 2013, 9:P139.
74. Alexander R, Budd S, Russell M, Kugler A, Cebers G, Ye N, Olsson T, Burdette D, Maltby J, Paraskos J, Elsby K, Han D, Goldwater R, Ereshefsky L: AZD3293 a novel bace1 inhibitor: safety, tolerability and effects on plasma and CSF Ab peptides following single- And multiple-dose administration. Neurobiol Aging 2014, 35:S2.
75. Höglund K, Salter H, Zetterberg H, Andreason U, Olsson T, Alexander R, Kugler A, Cebers G, Ye N, Burdette D, Budd Haeberlein SL: Monitoring the Soluble Amyloid Precursor Protein Alpha (SAPPA) and Beta (SAPPB) fragments in plasma and CSF from healthy individuals treated with bace inhibitor AZD3293 in a multiple ascending dose study: Pharmacokinetic and Pharmacodynamic correlate. Alzheimers Dement 2014, 10:P447.
76. Lai R, Albala B, Kaplow JM, Aluri J, Yen M, Satlin A: First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta-amyloid levels after single dosing. Alzheimers Dement 2012, 8:P96.
77. Lai R, Albala B, Kaplow JM, Majid O, Matijevic M, Aluri J, Satlin A: Novel BACE1 inhibitor E2609 reduces plasma and CSF amyloid in health subjects after 14 days oral administration. The 11th International Conference On Alzheimer's & Parkinson's Diseases, Florence, Italy, March 6-10, 2013.
78. Bernier F, Sato Y, Matijevic M, Desmond H, McGrath S, Burns L, Kaplow JM, Albala B: Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF. Alzheimers Dement 2013, 9:P886.
79. Chami L, Checler F: BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and beta-amyloid production in Alzheimer's disease. Mol Neurodegener 2012, 7:52.
80. Zhao Y, Wang Y, Yang J, Wang X, Zhao Y, Zhang X, Zhang YW: Sorting nexin 12 interacts with BACE1 and regulates BACE1-mediated APP processing. Mol Neurodegener 2012, 7:30.
81. Rossner S, Sastre M, Bourne K, Lichtenthaler SF: Transcriptional and translational regulation of BACE1 expression-implications for Alzheimer's disease. Prog Neurobiol 2006, 79:95-111.
82. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, Staufenbiel M, Huang LE, Song W: Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A 2006, 103:18727-18732.
83. Zhang X, Zhou K, Wang R, Cui J, Lipton SA, Liao FF, Xu H, Zhang YW: Hypoxiainducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem 2007, 282:10873-10880.
84. Sadleir KR, Eimer WA, Kaufman RJ, Osten P, Vassar R: Genetic inhibition of phosphorylation of the translation initiation factor eIF2α does not block Aβ-dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease. PLoS One 2014, 9.
85. Sadleir KR, Vassar R: Cdk5 protein inhibition and Abeta42 increase BACE1 protein level in primary neurons by a post-transcriptional mechanism: implications of CDK5 as a therapeutic target for Alzheimer disease. J Biol Chem 2012, 287:7224-7235.
86. Arbel M, Yacoby I, Solomon B: Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies. Proc Natl Acad Sci U S A 2005, 102:7718-7723.
87. Boddapati S, Levites Y, Sierks MR: Inhibiting beta-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP. J Mol Biol 2011, 405:436-447.
88. Rabinovich-Nikitin I, Rakover IS, Becker M, Solomon B: Beneficial effect of antibodies against beta- secretase cleavage site of APP on Alzheimer'slike pathology in triple-transgenic mice. PLoS One 2012, 7:e46650.
89. Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, Heise CE, Hoyte K, Luk W, Lu Y, Peng K, Wu P, Rouge L, Zhang Y, Lazarus RA, Scearce-Levie K, Wang W, Wu Y, Tessier-Lavigne M, Watts RJ: A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med 2011, 3:84ra43.
90. Zhou L, Chavez-Gutierrez L, Bockstael K, Sannerud R, Annaert W, May PC, Karran E, De Strooper B: Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1. J Biol Chem 2011, 286:8677-8687.
91. Wang W, Liu Y, Lazarus RA: Allosteric inhibition of BACE1 by an exositebinding antibody. Curr Opin Struct Biol 2013, 23:797-805.
92. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ, Dennis MS: Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011, 3:84ra44.
93. Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M, Maloney JA, Meilandt WJ, Bumbaca D, Gadkar K, Hoyte K, Luk W, Lu Y, Ernst JA, Scearce-Levie K, Couch JA, Dennis MS, Watts RJ: Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med 2014, 6:261ra154.
94. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y: Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A 2004, 101:3632-3637.
95. Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y: Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 2003, 9:3-4.
96. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC: Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 2002, 59:1381-1389.
97. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G: Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 2002, 51:783-786.
98. Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, Logan S, Maus E, Citron M, Berry R, Binder L, Vassar R: Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J Neurosci 2007, 27:3639-3649.
99. Zhang XM, Cai Y, Xiong K, Cai H, Luo XG, Feng JC, Clough RW, Struble RG, Patrylo PR, Yan XX: Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. Eur J Neurosci 2009, 30:2271-2283.
100. Torres M, Jimenez S, Sanchez-Varo R, Navarro V, Trujillo-Estrada L, Sanchez- Mejias E, Carmona I, Davila JC, Vizuete M, Gutierrez A, Vitorica J: Defective lysosomal proteolysis and axonal transport are early pathogenic events that worsen with age leading to increased APP metabolism and synaptic Abeta in transgenic APP/PS1 hippocampus. Mol Neurodegener 2012, 7:59.
101. Jack CR Jr: Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology 2012, 263:344-361.
102. Holtzman DM, Morris JC, Goate AM: Alzheimer's disease: The challenge of the second century. Sci Transl Med 2011, 3:77sr71.
103. Musiek ES, Holtzman DM: Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr Opin Neurol 2012, 25:715-720.
104. Tarawneh R, Holtzman DM: The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med 2012, 2:a006148.
105. Jack CR Jr, Holtzman DM: Biomarker modeling of Alzheimer's disease. Neuron 2013, 80:1347-1358.
106. Rosen C, Hansson O, Blennow K, Zetterberg H: Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener 2013, 8:20.
107. Lemere CA: Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener 2013, 8:36.
108. Salzer JL: Axonal regulation of Schwann cell ensheathment and myelination. J Peripher Nerv Syst 2012, 17:14-19.